Efficacy of Ertapenem for Treatment of Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

被引：49

作者：

Collins, Vicki L. ^{[1
]}

Marchaim, Dror ^{[1
]}

Pogue, Jason M. ^{[2
]}

Moshos, Judy ^{[1
]}

Bheemreddy, Suchitha ^{[1
]}

Sunkara, Bharath ^{[1
]}

Shallal, Alex ^{[1
]}

Chugh, Neelu ^{[1
]}

Eiseler, Sara ^{[1
]}

Bhargava, Pragati ^{[1
]}

Blunden, Christopher ^{[1
]}

Lephart, Paul R. ^{[3
]}

Memon, Babar Irfan ^{[1
]}

Hayakawa, Kayoko ^{[1
]}

Abreu-Lanfranco, Odaliz ^{[1
]}

Chopra, Teena ^{[1
]}

Munoz-Price, L. Silvia ^{[4
,5
]}

Carmenli, Yehuda ^{[6
]}

Kaye, Keith S. ^{[1
]}

机构：

[1] Wayne State Univ, Detroit Med Ctr, Div Infect Dis, Detroit, MI 48202 USA

[2] Wayne State Univ, Detroit Med Ctr, Dept Pharm Serv, Detroit, MI USA

[3] Wayne State Univ, Detroit Med Ctr, Dept Clin Microbiol, Detroit, MI USA

[4] Univ Miami, Dept Med, Div Infect Dis, Miami, FL USA

[5] Univ Miami, Dept Publ Hlth & Epidemiol, Miami, FL USA

[6] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Epidemiol, IL-69978 Tel Aviv, Israel

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2012年 / 56卷 / 04期

关键词：

KLEBSIELLA-PNEUMONIAE BACTEREMIA; TRIALS COMPARING ERTAPENEM; RISK-FACTORS; ANTIBIOTIC-THERAPY; MULTICENTER; CEFTRIAXONE; MANAGEMENT; RESISTANCE; IMIPENEM; ADULTS;

D O I：

10.1128/AAC.05913-11

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ertapenem is active against extended-spectrum-beta-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18).

引用

页码：2173 / 2177

页数：5

共 31 条

[1] Fighting bacterial resistance at the root: need for adapted EMEA guidelines [J].

Andremont, Antoine ;

Bonten, Marc ;

Kluytmans, Jan ;

Carmeli, Yehuda ;

Cars, Otto ;

Harbarth, Stephan .

LANCET INFECTIOUS DISEASES, 2011, 11 (01) :6-8

[2] Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrump-β-lactamase-producing Gram-negative organisms [J].

Bazaz, Rohit ;

Chapman, Ann L. N. ;

Winstanley, Trevor G. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (07) :1510-1513

[3] Efficacy of ertapenem for consolidation therapy of extended-spectrum β-lactamase-producing gram-negative infections:: A case series report [J].

Berg, Melody L. ;

Crank, Christopher W. ;

Philbrick, Alexander H. ;

Hayden, Mary K. .

ANNALS OF PHARMACOTHERAPY, 2008, 42 (02) :207-212

[4] Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli [J].

Bin, Cao ;

Hui, Wang ;

Zhu Renyuan ;

Ning Yongzhong ;

Xie Xiuli ;

Xu Yingchun ;

Zhu Yuanjue ;

Chen Minjun .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 56 (04) :351-357

[5] VALIDATION OF A PROGNOSTIC SCORE IN CRITICALLY ILL PATIENTS UNDERGOING TRANSPORT [J].

BION, JF ;

EDLIN, SA ;

RAMSAY, G ;

MCCABE, S ;

LEDINGHAM, IM .

BRITISH MEDICAL JOURNAL, 1985, 291 (6493) :432-434

[6]

Bonfiglio G, 2002, EXPERT OPIN INV DRUG, V11, P529

[7] Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].

Boucher, Helen W. ;

Talbot, George H. ;

Bradley, John S. ;

Edwards, John E., Jr. ;

Gilbert, David ;

Rice, Louis B. ;

Scheld, Michael ;

Spellberg, Brad ;

Bartlett, John .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12

[8] Clinical and microbiologic analysis of a hospital's extended-spectrum β-lactamase-producing isolates over a 2-year period [J].

Burgess, DS ;

Hall, RG ;

Lewis, JS ;

Jorgensen, JH ;

Patterson, JE .

PHARMACOTHERAPY, 2003, 23 (10) :1232-1237

[9]

Clinical and Laboratory Standards Institute, 2009, M100S19 CLSI

[10] Ertapenem - A review of its use in the management of bacterial infections [J].

Curran, MP ;

Simpson, D ;

Perry, CM .

DRUGS, 2003, 63 (17) :1855-1878

← 1 2 3 4 →